Fig. 1

Perceived Barriers to Buprenorphine and Extended-Release Naltrexone. Detailed Figure Summary: The most common barrier to prescribing buprenorphine, according to buprenorphine-waivered physicians (n = 47 respondents), was insurance prior authorization requirements (22%), followed by insufficient staff support (16%). Lack of support by managers/administrators at the practice was most commonly identified as a non-barrier (73%), followed closely by insufficient training (69%). As with buprenorphine, a commonly cited barrier to prescribing extended-release naltrexone (n = 97 respondents) was insurance prior authorization requirements, as well as the lack of community resources for patient withdrawal management (each 16.5%). Concern about diversion was the most commonly identified non-barrier to prescribing extended-release naltrexone (42%).